87 related articles for article (PubMed ID: 12165907)
1. [Expression of genes of potential importance in the response to chemotherapy in osteosarcoma patients].
Nathrath M; Kremer M; Letzel H; Remberger K; Höfler H; Ulle T
Klin Padiatr; 2002; 214(4):230-5. PubMed ID: 12165907
[TBL] [Abstract][Full Text] [Related]
2. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
3. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.
Mintz MB; Sowers R; Brown KM; Hilmer SC; Mazza B; Huvos AG; Meyers PA; Lafleur B; McDonough WS; Henry MM; Ramsey KE; Antonescu CR; Chen W; Healey JH; Daluski A; Berens ME; Macdonald TJ; Gorlick R; Stephan DA
Cancer Res; 2005 Mar; 65(5):1748-54. PubMed ID: 15753370
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of methotrexate resistance in osteosarcoma.
Guo W; Healey JH; Meyers PA; Ladanyi M; Huvos AG; Bertino JR; Gorlick R
Clin Cancer Res; 1999 Mar; 5(3):621-7. PubMed ID: 10100715
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
Patiño-García A; Zalacaín M; Marrodán L; San-Julián M; Sierrasesúmaga L
J Pediatr; 2009 May; 154(5):688-93. PubMed ID: 19159907
[TBL] [Abstract][Full Text] [Related]
6. Expression of major vault protein gene in osteosarcoma patients.
Dalla-Torre CA; de Toledo SR; Yoshimoto M; Petrilli AS; Andrade JA; Chilton-MacNeill S; Squire JA; Zielenska M
J Orthop Res; 2007 Jul; 25(7):958-63. PubMed ID: 17415755
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
[TBL] [Abstract][Full Text] [Related]
8. Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity.
Ifergan I; Meller I; Issakov J; Assaraf YG
Cancer; 2003 Nov; 98(9):1958-66. PubMed ID: 14584080
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.
Uchibori M; Nishida Y; Nagasaka T; Yamada Y; Nakanishi K; Ishiguro N
Int J Oncol; 2006 Jan; 28(1):33-42. PubMed ID: 16327977
[TBL] [Abstract][Full Text] [Related]
11. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
12. Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma.
Smida J; Baumhoer D; Rosemann M; Walch A; Bielack S; Poremba C; Remberger K; Korsching E; Scheurlen W; Dierkes C; Burdach S; Jundt G; Atkinson MJ; Nathrath M
Clin Cancer Res; 2010 Aug; 16(16):4256-67. PubMed ID: 20610556
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome.
Kersting C; Gebert C; Agelopoulos K; Schmidt H; van Diest PJ; Juergens H; Winkelmann W; Kevric M; Gosheger G; Brandt B; Bielack S; Buerger H
Clin Cancer Res; 2007 May; 13(10):2998-3005. PubMed ID: 17505002
[TBL] [Abstract][Full Text] [Related]
14. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Metzger R; Miyazono F; Baldus SE; Neiss S; Brabender J; Schaefer H; Doerfler W; Bollschweiler E; Dienes HP; Mueller RP; Danenberg PV; Hoelscher AH; Schneider PM
Clin Cancer Res; 2004 Jun; 10(11):3794-9. PubMed ID: 15173087
[TBL] [Abstract][Full Text] [Related]
15. Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles.
Ochi K; Daigo Y; Katagiri T; Nagayama S; Tsunoda T; Myoui A; Naka N; Araki N; Kudawara I; Ieguchi M; Toyama Y; Toguchida J; Yoshikawa H; Nakamura Y
Int J Oncol; 2004 Mar; 24(3):647-55. PubMed ID: 14767549
[TBL] [Abstract][Full Text] [Related]
16. Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas.
Park HR; Min K; Kim HS; Jung WW; Park YK
Pathol Res Pract; 2008; 204(8):575-82. PubMed ID: 18440723
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
18. [Neoadjuvant chemotherapy for osteosarcoma].
Guo W; Yang RL; Tang XD; Tang S; Li DS; Yang Y
Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(14):1186-90. PubMed ID: 15387981
[TBL] [Abstract][Full Text] [Related]
19. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study.
Wunder JS; Gokgoz N; Parkes R; Bull SB; Eskandarian S; Davis AM; Beauchamp CP; Conrad EU; Grimer RJ; Healey JH; Malkin D; Mangham DC; Rock MJ; Bell RS; Andrulis IL
J Clin Oncol; 2005 Mar; 23(7):1483-90. PubMed ID: 15735124
[TBL] [Abstract][Full Text] [Related]
20. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution.
Bacci G; Mercuri M; Longhi A; Ferrari S; Bertoni F; Versari M; Picci P
Eur J Cancer; 2005 Sep; 41(14):2079-85. PubMed ID: 16115755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
